Nano-Albumon (Human Serum Albumin)

Human serum albumin is the main protein responsible for maintaining colloid osmotic pressure in the blood. When infused, it raises the plasma albumin concentration, increasing oncotic pressure. This draws water from the interstitial space into the vascular compartment, expanding intravascular volume and supporting blood pressure and organ perfusion.

The prescribed dose of Nano-Albumon is determined by the treating physician based on the patient’s clinical condition, baseline albumin level, and required volume expansion. Dosing is individualized and may be expressed in grams or milliliters per kilogram of body weight, with adjustments made according to response and safety monitoring.

Safety data for Nano-Albumon in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To order Nano-Albumon, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the sales team provides pricing, availability, shipping details (including cold‑chain logistics if needed) and assists with import documentation.

Nano-Albumon, as a natural albumin solution, provides oncotic pressure similar to native plasma proteins, unlike synthetic colloids that may carry higher risks of coagulopathy or renal impairment. Compared with crystalloids, albumin achieves greater intravascular retention with smaller volumes, but it is more costly. Choice of therapy depends on clinical indication, patient status and cost considerations.

Nano-Albumon must be stored at 2‑8 °C (refrigerated). Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. Before use, inspect for particulate matter or discoloration and discard any product that appears compromised.

Nano-Albumon is administered by intravenous infusion, typically through a peripheral or central line. The infusion rate is set by the prescriber and may be adjusted based on the patient’s hemodynamic response and tolerance. Monitoring of vital signs, fluid balance and serum albumin levels is recommended during and after the infusion.

The most serious adverse events include anaphylactic or severe allergic reactions, volume overload leading to pulmonary edema, and rare occurrences of hemolysis or thrombosis. Prompt recognition and management of these reactions are essential, and patients should be closely monitored for signs of respiratory distress, sudden swelling, or changes in coagulation status.

Nano-Albumon is contraindicated in individuals with known hypersensitivity to human serum albumin or any excipients in the formulation. It should also be avoided in patients with uncontrolled heart failure, severe pulmonary edema, or active bleeding where additional volume expansion could worsen the condition. Clinical judgment is required for use in patients with renal impairment or other comorbidities.